We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) CEO For Now
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) CEO For Now
Key Insights
主要見解
- Eton Pharmaceuticals' Annual General Meeting to take place on 11th of June
- Salary of US$591.9k is part of CEO Sean Brynjelsen's total remuneration
- The overall pay is 103% above the industry average
- Eton Pharmaceuticals' EPS grew by 69% over the past three years while total shareholder loss over the past three years was 43%
- Eton Pharmaceuticals將於6月11日舉行年度股東大會。
- 董事長Sean Brynjelsen的總報酬中包括59.19萬美元的工資。
- 總收入比行業平均水平高出103%。
- 過去三年中,Eton Pharmaceuticals的每股收益增長了69%,而股東的總損失則下降了43%。
The underwhelming share price performance of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the past three years would have disappointed many shareholders. However, what is unusual is that EPS growth has been positive, suggesting that the share price has diverged from fundamentals. The AGM coming up on the 11th of June could be an opportunity for shareholders to bring these concerns to the board's attention. They could also influence management through voting on resolutions such as executive remuneration. We think shareholders might be reluctant to increase compensation for the CEO at the moment, according to our analysis below.
在過去的三年中,Eton Pharmaceuticals,Inc. (NASDAQ:ETON)的股價表現令很多股東失望。然而,其每股收益增長爲正,這表明股價與基本面偏離。6月11日的股東大會可能是股東將這些問題帶給董事會注意的機會。他們還可以通過對執行薪酬等決議進行投票影響管理層。根據我們的分析,我們認爲股東目前可能不願意增加CEO的報酬。
How Does Total Compensation For Sean Brynjelsen Compare With Other Companies In The Industry?
Sean Brynjelsen的總報酬與該行業中其他公司的情況相比如何?
Our data indicates that Eton Pharmaceuticals, Inc. has a market capitalization of US$93m, and total annual CEO compensation was reported as US$1.7m for the year to December 2023. Notably, that's a decrease of 18% over the year before. We think total compensation is more important but our data shows that the CEO salary is lower, at US$592k.
我們的數據顯示Eton Pharmaceuticals,Inc.的市值爲9300萬美元,截至2023年12月的首席執行官總年報酬爲170萬美元,而這是去年的18%的下降。值得注意的是,我們的數據顯示總報酬更重要,但首席執行官的工資較低,僅爲59.2萬美元。
In comparison with other companies in the American Pharmaceuticals industry with market capitalizations under US$200m, the reported median total CEO compensation was US$860k. Accordingly, our analysis reveals that Eton Pharmaceuticals, Inc. pays Sean Brynjelsen north of the industry median. What's more, Sean Brynjelsen holds US$3.9m worth of shares in the company in their own name, indicating that they have a lot of skin in the game.
與市值低於2億美元的美國製藥行業中的其他公司相比,總首席執行官報酬的中值爲86萬美元。因此,我們的分析表明Eton Pharmaceuticals,Inc.向Sean Brynjelsen支付的報酬高於行業中位數。此外,Sean Brynjelsen在公司名下持有390萬美元的股票,表明他在其中扮演着重要角色。
Component | 2023 | 2022 | Proportion (2023) |
Salary | US$592k | US$570k | 34% |
Other | US$1.2m | US$1.6m | 66% |
Total Compensation | US$1.7m | US$2.1m | 100% |
組成部分 | 2023 | 2022 | 比例(2023) |
薪資 | 59.2萬美元 | 570000美元 | 34% |
其他 | 120萬美元 | 160萬美元 | 66% |
總補償 | 170萬美元 | 210萬美元 | 100% |
Talking in terms of the industry, salary represented approximately 29% of total compensation out of all the companies we analyzed, while other remuneration made up 71% of the pie. Eton Pharmaceuticals is paying a higher share of its remuneration through a salary in comparison to the overall industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.
從行業角度來看,工資佔我們分析中所有公司的總薪酬的29%,而其他薪酬佔71%。Eton Pharmaceuticals較行業整體通過工資支付更高的薪酬份額。如果總報酬傾向於非工資福利,這表明首席執行官的報酬與公司業績相關。
![ceo-compensation](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240605/0-20a2c404b79ed2db46afb02a2dcbcaf1-0-424a55862d51f9552f924314515565f9.png/big)
Eton Pharmaceuticals, Inc.'s Growth
Eton Pharmaceuticals,Inc.的增長
Eton Pharmaceuticals, Inc. has seen its earnings per share (EPS) increase by 69% a year over the past three years. Its revenue is up 41% over the last year.
過去3年,Eton Pharmaceuticals,Inc.的每股收益年複合增長率爲69%,營業收入則增長了41%。
This demonstrates that the company has been improving recently and is good news for the shareholders. Most shareholders would be pleased to see strong revenue growth combined with EPS growth. This combo suggests a fast growing business. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings..
這表明公司近期有所改善,對於股東來說是個好消息。股東大多希望看到營收增長與每股收益增長相結合。這一組合意味着快速增長的業務。展望未來,您可能想查看分析師對該公司未來收益的預測的免費可視化報告。
Has Eton Pharmaceuticals, Inc. Been A Good Investment?
Eton Pharmaceuticals,Inc.是一項不錯的投資嗎?
Few Eton Pharmaceuticals, Inc. shareholders would feel satisfied with the return of -43% over three years. Therefore, it might be upsetting for shareholders if the CEO were paid generously.
在過去的3年中,Eton Pharmaceuticals,Inc.的回報率爲-43%。因此,如果首席執行官獲得慷慨的報酬,股東可能會感到失望。
In Summary...
總之……
The fact that shareholders are sitting on a loss on the value of their shares in the past few years is certainly disconcerting. The fact that the stock price hasn't grown along with earnings may indicate that other issues may be affecting that stock. If there are some unknown variables that are influencing the stock's price, surely shareholders would have some concerns. At the upcoming AGM, shareholders will get the opportunity to discuss any issues with the board, including those related to CEO remuneration and assess if the board's plan will likely improve performance in the future.
股東在過去幾年中持有的股票價值下降是令人擔憂的。股價沒有隨着收益增長而增長,這個事實可能意味着其他問題可能影響了該股票。如果有一些未知變量影響了股票價格,股東肯定會感到擔憂。在即將舉行的股東大會上,股東將有機會討論與董事會有關的任何問題,包括與首席執行官薪酬相關的問題,並評估董事會的計劃是否可能在未來改善業績。
While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. That's why we did some digging and identified 1 warning sign for Eton Pharmaceuticals that you should be aware of before investing.
儘管關注首席執行官的報酬很重要,投資者也應考慮業務的其他方面。這就是爲什麼我們進行了一些調查,並確定了Eton藥品的1個警告信號,您在投資之前應該注意。
Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.
當然,你可能會通過觀察其他股票的不同漲跌幅來找到一筆不錯的投資。所以,可以看一下這個有趣的公司的免費列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。